Brii Biosciences LtdHKG 2137 Stock Report

Brii Biosciences Ltd. engages in advancing therapies for significant infectious diseases and other illnesses which have significant public health burdens. The company is headquartered in Beijing, Beijing and currently employs 123 full-time employees. The company went IPO on 2021-07-13. The Company’s products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens. The firm is also developing therapies for COVID-19 and other diseases.